Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Pucotenlimab in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07524452Phase 3Recruiting
- Start
- Feb 2026
- Primary completion
- Feb 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC) (2 arms). Primary endpoint: Event-Free Survival Rate at 3 years. Started Feb 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07524452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524452.